Evidence map›Paper›PMID 26622625›Full record

ArticleOncology letters2015

Clinico-epidemiology of neuroblastoma in north east Egypt: A 5-year multicenter study.

Youssef Al-Tonbary, Mohamed Badr, Ahmed Mansour, Usama El Safy, Shebl Saeed, Tamer Hassan, Rasha Elashery, Rofida Nofal, Ahmad Darwish

Abstract read
In one paragraph

Article in Oncology letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Management of neuroblastoma in limited-resource settings.World journal of clinical oncology · 2020
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Youssef Al-TonbaryDepartment of Pediatric Hematology and Oncology, Mansoura University Children's Hospital, Mansoura, Dakahlia 35516, Egypt.
Mohamed BadrDepartment of Pediatric Hematology and Oncology, Zagazig University Children's Hospital, Zagazig, Sharqia 44111, Egypt.
Ahmed MansourDepartment of Pediatric Hematology and Oncology, Mansoura University Children's Hospital, Mansoura, Dakahlia 35516, Egypt.
Usama El SafyDepartment of Pediatric Hematology and Oncology, Zagazig University Children's Hospital, Zagazig, Sharqia 44111, Egypt.
Shebl SaeedDepartment of Pediatric Hematology and Oncology, Tanta University Children's Hospital, Tanta, Gharbia 31111, Egypt.
Tamer HassanDepartment of Pediatric Hematology and Oncology, Zagazig University Children's Hospital, Zagazig, Sharqia 44111, Egypt.
Rasha ElasheryDepartment of Pediatric Hematology and Oncology, Mansoura University Children's Hospital, Mansoura, Dakahlia 35516, Egypt.
Rofida NofalDepartment of Pediatric Hematology and Oncology, Zagazig University Children's Hospital, Zagazig, Sharqia 44111, Egypt.
Ahmad DarwishDepartment of Pediatric Hematology and Oncology, Mansoura University Children's Hospital, Mansoura, Dakahlia 35516, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroblastoma, an embryonal malignancy of the sympathetic nervous system, is the most frequent extracranial solid tumor The clinico-epidemiological features of neuroblastoma in infants and children were investigated between January 2005 and January 2010 at the Pediatric Oncology units of Mansoura, Zagazig, and Tanta University Children's Hospitals (Egypt). Of 142 cases of neuroblastoma, 10 were omitted from the study due to defective data. The median age of the patients was 30 months, with 75.8% aged ≥1 year and 24.2% aged <1 year at time of diagnosis. The male-to-female ratio was 1.06. Suprarenal glands were the most common primary tumor site (72.7%). The majority of the patients (76.7%) had stage IV disease. Favorable pathology was observed in 43.8% of patients, while 56.2% exhibited unfavorable pathology. The estimated survival rate of patients was 30.7±10.0%, and mean survival time was 24.2±5.2 months. The rate of mortality was 28.6% for patients aged <1 year, and 81.8% for those aged ≥1 year (P=0.005). For patients with favorable pathology, the rate of mortality was significantly lower (28.6%) compared with that of patients with unfavorable pathology (77.8%; P=0.049). Although the association between outcome and each of the primary tumor sites, children's oncology group risk and gender was statistically insignificant, a large effect size was identified between outcome and primary tumor site, as well as children's oncology group risk and a medium effect size was identified between outcome and gender. Additionally, an age of ≥1 year was associated with unfavorable pathology (P=0.024), stage IV disease (P=0.026) and a suprarenal primary tumor site (P=0.001).

Indexed as

epidemiologyneuroblastoma

Identifiers

PMID26622625
PMCPMC4509073

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.